Robert M Berne

US Patent:

46735631, Jun 16, 1987

Filed:

Apr 8, 1985

Appl. No.:

6/721122

Inventors:

Robert M. Berne - Charlottesville VA
Luiz Belardinelli - Charlottesville VA
Rafael Rubio - Charlottesville VA

Assignee:

The University of Virginia Alumni Patents Foundation - Charlottesville VA

International Classification:

A61K 4900
A61K 3170

US Classification:

424 9

Abstract:

A method of diagnosing and treating arrhythmias caused by re-entry in the A-V node by administering to a human or animal an effective amount of adenosine that restores normal sinus rhythm.

US Patent:

48807834, Nov 14, 1989

Filed:

Sep 29, 1988

Appl. No.:

7/252027

Inventors:

Robert M. Mentzer - Charlottesville VA
Stephen W. Ely - Charlottesville VA
Robert D. Lasley - Charlottesville VA
Robert M. Berne - Charlottesville VA

Assignee:

University of Virginia Alumnia Patents Foundation - Charlottesville VA

International Classification:

A61K 3170

US Classification:

514 46

Abstract:

The invention relates to an improved cardioplegic solution for reducing ischemic damage to the heart during operations and/or transplantation. The invented solution contains adenosine, hypoxanthine and ribose in addition to the electrolytes contained in standard cardioplegic solutions.

US Patent:

43649220, Dec 21, 1982

Filed:

Oct 14, 1980

Appl. No.:

6/196652

Inventors:

Robert M. Berne - Charlottesville VA
Luiz Belardinelli - Charlottesville VA
Rafael Rubio - Charlottesville VA

Assignee:

University of Virginia Alumni Patents Foundation - Charlottesville VA

International Classification:

A61K 4900
A61K 3152
A61K 3146

US Classification:

424 9

Abstract:

A method of relieving atrioventricular conduction block by administering to a human or animal an effective amount of an adenosine antagonist that competitively inhibits adenosine or that reduces the level of adenosine present in myocardial tissue and associated fluids. A method of diagnosing atrioventricular conduction block caused by ischemia of the heart by measuring the time delay between atrial and ventricular excitation before and after the administration of an adenosine antagonist. Specific antagonists disclosed include methylxanthines.